What's Next For Bristol's Opdivo/Yervoy Combination
This article was originally published in The Pink Sheet Daily
Updated data from CheckMate 012 of Yervoy/Opdivo in first-line lung cancer bode well for the Phase III CheckMate 227 study, plus other indications, Bristol says.
You may also be interested in...
Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing
Bristol-Myers Squibb's decision not to seek accelerated FDA approval for its Opdivo/Yervoy combo in early lung cancer shocked investors - but analysts still expect a filing to come, albeit later than first thought.
Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology
Merck’s strong Phase II data testing Keytruda with chemotherapy in first-line lung cancer may put pressure on future IO/IO combinations when it comes to toxicity, efficacy and – importantly – cost.
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
Things couldn't have gone any worse for Bristol-Myers Squibb's Opdivo in the CheckMate 026 lung cancer data presented at ESMO. Without even a trend towards efficacy in patients with high levels of PD-L1 expression, imminent erosion of market share by Merck's Keytruda seems inevitable.